In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Paul Dickinson, Founder and CSO at Seda Pharmaceutical Development Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Paul, covering:

• The success factors and a behind-the-scenes look at one of AstraZeneca’s fastest development programs – from the start of clinical trials to approval in just over two and a half years to meet unmet lung cancer needs

Paul has held several senior science leadership roles in Academia and Large Pharma. These roles focussed on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines. He founded Seda Pharmaceutical Development Services, a company focused on delivering pharmaceutical development (CMC) and clinical pharmacology services to the Pharma industry.

Prior, Paul led AstraZeneca’s clinical pharmacology program to NDA/MAA for AZD9291, which was the highest priority project in the AZ development portfolio and had been awarded ‘breakthrough therapy’ status by the FDA. As a result of both his internal and external scientific leadership, he has been awarded numerous science and innovation awards by AstraZeneca. Paul has published >30 research papers, 5 patents, 2 book chapters, and presented numerous invited lectures and conference abstracts.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.